Clinical Trial Update: Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11.2 deletion syndrome; Phase 2/Phase 3, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• 22q11 Deletion Syndrome

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Bambino Gesù Hospital and Research Institute | Conditions: 22q11 Deletion Syndrome | Phase 2, Phase 3 | Status: UNKNOWN